ERBB2 and breast carcinoma: This finding aligns with previously published views, such as the strong antitumor activity of T-DM1 in treating HER2-positive breast cancer patients (51); ADCs have great potential in treating solid tumors, particularly in extending survival time for patients with HER2 IHC 3+ mutations (52).